Yang Su

Papers

Total Citations

H-Index

About

Dr. Yang Su is pioneering the future of precision medicine through groundbreaking work in artificial biomarker-guided thrombolysis, a field at the intersection of nanomedicine, bioengineering, and clinical therapeutics. Their most cited research, published in 2025, addresses a critical clinical challenge: the high risk of hemorrhage and low recanalization rates in current body weight-based thrombolytic therapies. By revealing the relationship between thrombus heterogeneity and thrombolysis resistance, Dr. Su developed a feedback-regulated, personalized system that uses artificial biomarkers to dynamically adjust treatment in real time, dramatically lowering hemorrhagic risk while improving efficacy. This work, already garnering 6 citations in its first year, represents a paradigm shift from one-size-fits-all dosing to truly individualized intervention. Dr. Su’s contributions are particularly notable for bridging the gap between bench-side biomarker discovery and bedside clinical application, offering a tangible solution to one of stroke therapy’s most persistent dilemmas. Their research stands as a vital resource for students and clinicians seeking to understand how smart biomaterials and adaptive algorithms can transform acute care, making thrombolysis safer and more effective for diverse patient populations.